Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base 

Published byBryan Holt Modified over 5 years ago

Similar presentations

Presentation on theme: "Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base "— Presentation transcript:

1 Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base  Amy C. Moreno, BA, Daniel Morgensztern, MD, Daniel J. Boffa, MD, Roy H. Decker, MD, PhD, James B. Yu, MD, Frank C. Detterbeck, MD, Zuoheng Wang, PhD, Michal G. Rose, MD, Anthony W. Kim, MD  The Annals of Thoracic Surgery  Volume 97, Issue 4, Pages (April 2014) DOI: /j.athoracsur Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Overall survival estimates for overall cohort stratified by type of primary therapy. (NST = nonsurgical therapy; PST = primary surgical therapy.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Overall survival estimates for (A) nonsurgical therapy and (B) primary surgical therapy cohorts stratified by type of therapy. (C-S = neoadjuvant chemotherapy + surgery; CxR = chemoradiation; CxR-S = neoadjuvant chemoradiation + surgery; RT = radiation therapy; S = surgery; S-C = surgery + adjuvant chemotherapy; S-CxR = surgery + adjuvant chemoradiation; S-PORT = surgery + postoperative radiation therapy.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base "

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R

Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Roland Assi, MD, MMS, Daniel J. Wong, MD, Daniel J. Boffa, MD, Frank C

Roland Assi, MD, MMS, Daniel J. Wong, MD, Daniel J. Boffa, MD, Frank C
Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database 

Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database 
Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database  Daniel J. Boffa,

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database  Daniel J. Boffa,
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer
Ravi Rajaram, MD, MSc, Jennifer L

Ravi Rajaram, MD, MSc, Jennifer L
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.
Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis  Andrew J. Graham, MD, MS, Fiona M. Shrive,

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis  Andrew J. Graham, MD, MS, Fiona M. Shrive,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Similar presentations

Ads by Google